| Autor: |
Temaj G; Faculty of Pharmacy, College UBT, 10000 Prishtina, Kosovo., Chichiarelli S; Department of Biochemical Sciences 'A. Rossi-Fanelli', Sapienza University of Rome, 00185 Rome, Italy., Saha S; Department of Biotechnology, Institute of Applied Sciences & Humanities, GLA University, Mathura 00185, Uttar Pradesh, India., Telkoparan-Akillilar P; Department of Medical Biology, Faculty of Medicine, Gazi University, 06500 Ankara, Turkey., Nuhii N; Department of Pharmacy, Faculty of Medical Sciences, State University of Tetovo, 1200 Tetovo, North Macedonia., Hadziselimovic R; Faculty of Science, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina., Saso L; Department of Physiology and Pharmacology 'Vittorio Erspamer', La Sapienza University, 00185 Rome, Italy. |
| Abstrakt: |
Leukemia represents the most prevalent malignancy in children, constituting 30% of childhood cancer cases, with acute lymphoblastic leukemia (ALL) being particularly heterogeneous. This paper explores the role of alternative splicing in leukemia, highlighting its significance in cancer development and progression. Aberrant splicing is often driven by mutations in splicing-factor genes, which can lead to the production of variant proteins that contribute to oncogenesis. The spliceosome, a complex of small nuclear RNAs and proteins, facilitates RNA splicing, a process critical for generating diverse mRNA and protein products from single genes. Mutations in splicing factors, such as U2AF1, SF3B1, SRSF2, ZRSR2, and HNRNPH1, are frequently observed across various hematological malignancies and are associated with poor prognosis and treatment resistance. This research underscores the necessity of understanding the mechanisms of RNA splicing dysregulation in order to develop targeted therapies to correct these aberrant processes, thereby improving outcomes for patients with leukemia and related disorders. |
